FDA Approves Expansion of Alzheimer's Disease Microsurgical Study

MMI (Medical Microinstruments, Inc.) announced that the U.S. Food and Drug Administration (FDA) has approved the expansion of its Investigational Device Exemption (IDE) for the REMIND study. This approval allows for increased patient enrollment beyond the initial cohort to the full early feasibility study population of 15 patients. The study explores robotic-enabled microsurgical intervention to re-establish lymphatic drainage pathways in patients with Alzheimer's disease and confirmed lymphatic abnormalities.